In developing treatment programmes that follow the principle of individualized treatment, care should be taken to check the patient ‘ s history of the application of antibiotics, avoiding the need to avoid the selection of antibiotics that can easily lead to subsequent resistance; to re-evaluate patients who have failed in two formal treatments, and to consider the use of sensitive antibiotics for patients who need treatment; and to reduce the use of unnecessary antibiotics and the spread of resistant strains as the problem of claustrophax antibiotic resistance increases, as a result of the development and clinical application of the commercial chemical reagent box for bacterial resistance testing, such as the ability to conduct drug resistance tests for bacteria before the patient ‘ s first treatment, and to select sensitive antibiotics, not only to improve the efficacy of the first treatment, but also to reduce the use of unnecessary antibiotics and the spread of resistant strains. Research suggests that the smaller the number of successful eradication treatments, the greater the benefit from cholesterocococcal eradication treatments, the greater the first-time treatments, the more successful patients, the reason may be considered to be related to the lower the variety of antibiotics used in the treatment, the smaller the impact of antibiotics on the intestinal tract microecological environment of the infected person and the shorter the duration.
Increased patient dependence in the choice of treatment methods is informed about the characteristics of the treatment, and is fully informed about the patient ‘ s history of sex, age, height, weight, combination of underlying diseases and use of drugs, history of past antibiotic application, drug allergies, etc., with a view to avoiding drug interaction, individualization of reasonable treatment options to reduce the risk of adverse response; adequate communication with the patient before treatment, understanding of the strength of the patient ‘ s willingness to treat, and informing him/her about the detailed treatment methods and possible adverse reactions in the treatment can increase the patient ‘ s dependence and reduce the risk of treatment failure.
Quadripartite therapy, which explores the feasibility of other programmes for treatment of patients in China, which do not contain a herbicide, is not recommended at the national level: for example, a combination therapy (PPI+ three antibiotics), a sequence of treatments (PPI+Amosilin five days before, PPI+caracin and americium five days later), a combination therapy, etc., has not been recommended in the country, where some clinical studies have shown that the treatment has been less effective. The four-pronged treatment of americium is the preferred option recommended in the Chinese consensus in recent years.
High-dose combination therapy is worth further exploration: the high-dose combination therapy consists of PPI+Amosicillin, with a general course of 14d. The programme has increased its eradication rate by increasing the frequency and dosage of PPI and Amosilin, as appropriate. Recent studies in the country have shown that the programme has good prophylactic effects for Chinese patients, and that the incidence of adverse reactions among patients is significantly lower than that of americin-containing four-stage therapy. The programme has been recommended for clinical eradication treatment by the American Society of Gastrointestinal Diseases (ACG) in its Clinical Guide on Sphinx Spectrum Clinical Care published in 2017. The recent clinical application of a new generation of reversible potassium ion competitive acid retardant (P-CAB) has provided new possibilities for increasing the success rate of eradication of cholesterocella, especially with regard to the application of DPT.
Assistive treatment can reduce antibiotics-related adverse effects and increase eradication effectiveness, and non-antibiotic assistive therapy is beginning to gain the attention of researchers as the problem of cholesterocella antibiotic resistance increases. The application of prophylactic bacteria in treatment programmes can reduce adverse patient reactions and thus increase patient dependence on treatment. The development of anti-bacterial plant drugs, also a hot spot for recent research, has revealed a variety of plant components that are anti-bacterial to the cyanobacteria, which, in association with antibiotics, reduce the resistance to bacterial antibiotics and co-activate resistance. The search for new non-antibiotic drugs and research into the development of vaccines to increase the effectiveness of the eradication of the fungus, to reduce the pathogenicity of the fungus or to reduce adverse effects in treatment is a trend for future research.
